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a  b  s  t  r  a  c  t
The  HIV  epidemic  is greatest  in Sub-Saharan  Africa  and  India  where  HIV-1  subtype  C is  predominant.  To
control  the spread  of HIV in these  parts  of  the  world  a preventive  HIV-1  subtype  C  vaccine  is  urgently
required.  Here  we  report  the  immunogenicity  of  a candidate  HIV-1  subtype  C  vaccine  delivered  by  a
recombinant  measles  vector carrying  an  insert  encoding  HIV-1  subtype  C  Gag,  RT  and Nef (MV1-F4),  in
MHC-typed  non-human  primates.  HIV-1  speciﬁc  cytokine  secreting  CD4+  and CD8+  T cell  responses  were






HIV-1 antibody  responses  were  detected  in  15  out  of 16 vaccinees  and  titres  were  boosted  by  a  second
immunisation  carried  out  84  days  later.  These  ﬁndings  support  further  exploration  of  the  MV1-F4  vector
as a candidate  HIV-1  subtype  C vaccine  or as  part  of  a wider  vaccine  strategy.
© 2013 The Authors. Published by Elsevier Ltd. All rights reserved.umoral responses
. Introduction
During 2004–2007, HIV-1 subtype C (HIV-1C) accounted for 48%
f all global infections compared to just 11% for subtype B [1]. This
igh prevalence of HIV-1C is due to its predominance in south-
rn Africa, east Africa and India [1], where an effective vaccine to
imit the spread of HIV-1C is desperately needed. Phase I trials of
IV-1C candidate vaccines, based upon modiﬁed vaccinia Ankara
nd recombinant adeno-associated virus vaccine vector candidates
ave been conducted in India [2,3], but generated modest immune
esponses. Similarly, the phase I trial of an alphavirus replicon
IV-1C gag vaccine (AVX101) generated low levels of binding anti-
odies and T-cell responses [4]. Alternative approaches need to be
xplored in order to provide a better HIV-1C vaccine vector candi-
ate.Live attenuated measles virus (MV) is proven to be one of the
afest and most effective human vaccines to date inducing life-
ong immunity after a single or two low-dose injections [5]. The
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ttp://dx.doi.org/10.1016/j.vaccine.2013.09.072MV  genome is very stable and reversion to pathogenicity has never
been observed [6]. MV  replicates exclusively in the cytoplasm rul-
ing out the possibility of integration into host cell DNA. A reverse
genetics system for MV has been established [7], allowing the
production of recombinant MV with additional foreign genetic
material [8]. Various vectors based upon measles vaccine strains
have been developed to express stably a variety of genes, or com-
binations of genes, of large size over more than twelve passages
[9–19]. Immunisation with these vectors has been shown to induce
long-lasting humoral and cellular immune responses to the trans-
genes, even in presence of pre-existing immunity to MV  [11–19].
Here, we have generated a recombinant measles vector express-
ing the F4 antigen [20], a fusion protein consisting of HIV-1C
Gag p17, Gag p24, Nef and reverse transcriptase (RT). The
immunogenicity of the resulting MV1-F4 candidate HIV-1C vaccine
was investigated in MHC-typed, Mauritian-derived cynomolgus
macaques. Here we show that vaccination with MV1-F4 induced
cellular immune responses against the HIV-1C F4 insert and
humoral responses that were boostable, resulting in increased
immunogenicity. Furthermore, long lasting F4-speciﬁc CD8+ T
cell responses were detected in secondary lymphoid organs of
vaccinated cynomolgus macaques consistent with the observed
persistence of anti-MV CD8+ T cell responses detectable up to 25
years after human vaccination [21]. These results demonstrate that
MV1-F4 is a suitable HIV-1C candidate vaccine vector for evaluation
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. Materials and methods
.1. Recombinant vaccine vector generation
The plasmid pTM-MV Schw carries an infectious cDNA corre-
ponding to the anti-genome of the Schwarz MV  vaccine strain
11]. A cDNA encoding for the HIV-1C F4 fusion protein sequence
as chemically synthesized and optimized for measles virus
xpression in mammalian cells and inserted into the ATU of
TM-MV Schw vector resulting in the plasmid pTM-MVSchw-
TU2 F4co mut. The F4 antigen comprises HIV-1C p17, p24, RT
nd Nef based upon a consensus sequence retrieved from HIV
atabases, (http://www.hiv.lanl.gov), codon optimized for eukary-
te expression. The corresponding MV1-F4 virus was  rescued
rom the pTM-MVSchw-ATU2 F4co mut  plasmid using a helper
ell-based system and ampliﬁed using MRC-5 cells as previously
escribed [11,19].
.2. Study design and animals
Purpose-bred, Mauritian-derived cynomolgus macaques
Macaca fascicularis) were chosen as this species is susceptible
o infection with wild-type MV [22,23]. Seven common haplo-
ypes (designated M1–M7) account for 99% of MHC  class I and II
iversity in Mauritian-derived cynomolgus macaques [24,25]. This
estricted MHC  diversity makes it possible to relate cell-mediated
mmune responses to haplotype [24,25]. MHC  haplotypes of stock
acaques were determined by microsatellite PCR, as described
reviously [25]. Eight pairs of MHC-matched D-type retrovirus-free
uvenile male macaques were selected and corresponding animals
ivided equally between groups A and B (Table 1). Macaques
ith complex recombinant MHC  haplotypes were matched to
he most closely related animal available. Group A, macaques
21–H28, and Group B, macaques H29–H36, were vaccinated
.m. with 104 TCID50 and 105 TCID50 MV1-F4, respectively on
ay 0. Both groups received a boost on day 84, with the same
ose of vaccine. Peripheral blood mononuclear cells (PBMC) were
solated by Percoll density gradient centrifugation (Sigma–Aldrich)
s previously described [26]. Spleen, peripheral and mesenteric
ymph nodes were collected at termination, between days 196
nd 201, cells isolated using a Medimachine tissue-homogenizer
BD Bioscience), and cryopreserved for later analysis. Serum and
lasma were collected and stored at −20 ◦C for later analysis.
Non-human primates were used in strict accordance with UK
ome Ofﬁce guidelines. The work at NIBSC was governed by the
nimals Scientiﬁc Procedures Act 1986, which complies with the EC
irective 86/609. The work was performed under licence granted
nly after review of all the procedures by a local Ethical Review
rocess. All macaques were sedated with ketamine hydrochloride
efore vaccination or venepuncture and killed humanely at end of
tudy by an overdose of anaesthetic.
.3. Cellular immune responses
Cytokine responses were detected by polyfunctional ﬂow
ytometry following stimulation of lymphocytes from peripheral
lood and lymphoid tissues with synthetic peptide pools covering
he HIV-1C insert, as previously described [19]. Cells were stimu-
ated in triplicate with synthetic 15-mer (overlapping by 11)
eptide pools covering HIV-1C p24, p17, RT and Nef sequences
GlaxoSmithKline) at 1 g/ml/peptide or a live attenuated empty
V at 104 TCID50/106 cells, in the presence of 1 g/ml of the co-
timulatory antibodies anti-CD28 and CD49d (Biolegend). Negative
ontrols were incubated with an equal volume of DMSO (0.15%, v/v)31 (2013) 6079– 6086
without peptide and positive controls with 1 g/ml Staphylococcal
Enterotoxin B (Sigma–Aldrich).
2.4. Humoral immune responses
HIV-1C-speciﬁc binding antibodies were determined in mon-
key plasma samples using an enzyme-linked immunosorbent assay
(ELISA) as previously described [19] except that plates were coated
with HIV-1C F4 antigens (GSK Biologicals). Measles neutralising
antibody responses were detected using a plaque reduction assay
as previously described [19].
2.5. Statistical analysis
Cytokine responses against 4 peptide pools, p17, p24, RT and Nef
were summed to give a total response against the HIV-1C insert.
Background responses against DMSO controls were subtracted
from individual peptide pool result before summation. Cytokine
responses for CD4+ and CD8+ T cell were calculated separately.
Cytokine responses greater than the mean plus 3 standard devi-
ations of day 0 responses were deemed signiﬁcant. All statistical
analysis was  performed using Prism 5 (Graph Pad Software).
3. Results
3.1. Vaccination with MV1-F4 induced CD4+ and CD8+ T
responses to HIV-1
Both CD4+ and CD8+ T cell cytokine responses were detected
by ﬂow cytometry following in vitro stimulation of macaque PBMC
with HIV-1C peptide pools (Fig. 1), and the activation marker CD154
was co-expressed by most cytokine positive CD4+ T cells (Fig. 1,
shown in red).
Signiﬁcant CD4+ T cell cytokine responses against HIV-1C pep-
tide pools were detected in 13 out of 16 macaques after the ﬁrst
immunisation and all 16 after the boost, of which two were weak
(Fig. 2A and B). Potent CD4+ T cell cytokine responses, greater than
twice the cut-off value for signiﬁcance, were measured in 11 vac-
cinees. The exceptions were macaques H21, H28, H29, H33 and
H34 where cytokine responses were only just above cut-off at one
or more time-points (Fig. 2A and B). Initially, CD4+ T cell cytokine
responses peaked between days 14 and 56 in groups A (104 TCID50
MV1-F4 i.m.) and B (105 TCID50 MV1-F4 i.m.), but had declined
by day 84 when the same boost was  administered (Fig. 2A and B).
Between days 98 and 140, CD4+ T cell cytokine responses to HIV-
1C peptides were re-stimulated, with peak responses equivalent to
or greater than those detected after the ﬁrst immunisation. There-
after, peripheral CD4+ T cell responses declined with time, but low
level sporadic responses could still be detected in spleen whereas
BLN were essentially negative (Fig. 2A and B).
Signiﬁcant CD8+ T cell responses against HIV-1C peptides were
detected in 13 out of 16 vaccinees (Fig. 2C and D). However,
the frequencies of CD8+ T cell cytokine responses were moder-
ate by comparison with CD4+ responses. Peripheral CD8+ T cell
responses against F4 peptides remained relatively stable after the
ﬁrst immunisation such that no detectable re-stimulation was
noted after the second immunisation (Fig. 2C and D). At termination
CD8+ T cell responses measured in spleen remained high in a few
vaccinees (Fig. 2C and D). Overall, the frequency of T cell responses
between groups A and B were comparable.
In vaccinees, CD4+ responses to F4 peptides were mostly sin-
gle cytokine positive, TNF+ or IL-2+, and dual cytokine positive,
TNF+ and IL-2+, T cells (Fig. 3A and B). By contrast, CD8+ responses
against F4 peptide comprised of mostly single cytokine positive,
TNF+ or IFN+, T cells (Fig. 3C and D). Mean CD4+ T cell cytokine
responses peaked 28 days after the ﬁrst immunisation and 14 days
R. Stebbings et al. / Vaccine 31 (2013) 6079– 6086 6081
Table 1
MHC  haplotype analysis of vaccinees. MHC  haplotypes of MV1-F4 vaccinees, F51–F58, determined by
microsatellite analysis. Haplotypes with recombination were resolved by allele-speciﬁc PCR. Intact
haplotypes, M1–M7, have been previously identiﬁed in Mauritian cynomolgus macaques [24,25].
Mean MHC  class I restricted CD8+ T cell and MHC  class II restricted CD4+ T cell cytokine responses
post vaccination (days 14–196) are shown, ±SEM. Signiﬁcant responses (above mean plus 3 standard
deviations of day 0 responses) are shown in bold.
Grou p Animal Class  IA Class  IB Mea n CD 8+ Class  II Mea n CD 4+
% Cytokine+ % Cytokine+
A H21 M1 M1 0.52  ± 0.15 M1 0.58  ± 0.16
M3 M3 M3
H22 M1 M1 0.32  ± 0.06 M1 1.52  ± 0.19
M3 M3 M3
H23 M2 M2 0.55  ± 0.07 M2 1.96  ± 0.35
M3 M3 M3
H24 M1 M1 0.47  ± 0.07 M1 3.76  ± 0.84
M3 M2 + M3 M2
H25 M3 M3 0.34  ± 0.04 M3 2.47  ± 0.55
M2 M4 M4
H26 M6 M6 0.30  ± 0.07 M4 + M6 3.59  ± 0.47
M1 M1 M4
H27 M3 M3 0.23  ± 0.03 M3 4.36  ± 0.63
M6 M6 M2 + M6
H28 M3 M3 0.04  ± 0.01 M3 0.37  ± 0.12
M4 M1 + M4 M2
B H29 M1 M1 0.07  ± 0.02 M1 0.64  ± 0.08
M3 M3 M3
H30 M1 M1 0.41  ± 0.10 M1 1.73  ± 0.39
M3 M3 M3
H31 M2 M2 0.83  ± 0.13 M2 2.46  ± 0.52
M3 M3 M3
H32 M1 M1 0.28  ± 0.07 M1 0.80  ± 0.20
M3 M2 + M3 M2
H33 M3 M3 0.33  ± 0.07 M3 0.53  ± 0.13
M2 M4 M4
H34 M6 M3 0.41  ± 0.05 M3 0.56  ± 0.05
M4 M1 + M4 M2
H35 M3 M3 0.27  ± 0.03 M3 3.57  ± 0.81
M2 + M3 M2 M2
H36 M3 M3 0.37  ± 0.02 M3 0.71  ± 0.26
M1 M1 + M2 M2
Fig. 1. Representative dot plots of PBMC stimulated overnight with p17 (A and B) or Nef (C and D) HIV-1 subtype C peptide pools. Analysis is gated on CD4+ (A and B)
and  CD8+ (C and D) T cells from MV1-F4 immunised macaques H31, respectively. Blue events represent CD4+CD154− and red CD4+CD154+ T cells (A and B). Green events
represent CD8+ T cells (C and D). Intracellular cytokine staining for TNF versus IL-2 (A and C) and TNF versus IFN (B and D) is shown. Percentages shown represent the
proportion of events in respective quadrants.
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Fig. 2. T cell cytokine responses to HIV-1 subtype C peptides following vaccination with MV1-F4. Total cytokine (sum of TNF+, IL-2+ and IFN+ cells) response to HIV-1
subtype  C peptides by CD4+ and CD8+ T cells from peripheral blood, brachial lymph nodes (BLN) and spleen (SPL). Time in days is shown on x-axis, all responses from PBMC
u 9–H3























1nless  preﬁxed by a tissue. Group A, macaques H21–H28 and group B, macaques H2
nd  84. Panels A and B shows cytokine responses gated on CD4+ T cells. Panels C an
 standard deviations of day 0 responses, above which points were deemed signiﬁc
fter the second (Fig. 3A and B). It was not possible to discern clear
eaks in mean CD8+ T cell responses, due to lower responses and
igher variability (Fig. 3C and D). More double cytokine positive
D4+ T cell responses were observed in group A compared to B.
riple cytokine positive CD4+ and CD8+ T cell responses were very
ow in both groups. The cytokine responses of peripheral CD4+
TNF and IL-2) and CD8+ (TNF and IFN) T cells responding to
IV-1C peptides did not differ from lymphoid tissue T cells (Fig. 3).
Signiﬁcant CD4+ and much lower CD8+ T cell cytokine responses
gainst MV were detected in most vaccinees (Fig. 4). Anti-MV T
ell cytokine responses were also detected in the lymphoid tissues
f most vaccinees (Fig. 4). Overall, comparable levels of responses
ere observed between groups A and B (Fig. 4).
.2. Vaccination with MV1-F4 induced boostable humoral
esponses
After the ﬁrst immunisation 5 out of 8 in group A and 7 out of 8 in
roup B seroconverted to F4 antigen (Fig. 5A and B). This increased
o 7 out of 8 in group A and 8 out of 8 in group B after the sec-
nd immunisation (Fig. 5A and B). Peak titres in both groups were
oosted after the second immunisation (Fig. 5A and B). Peak titres in
roup B were approximately 10-fold higher than group A after the
econd immunisation. Only vaccine recipient H24 in group A did
ot seroconvert to the F4 antigen (Fig. 5A). Nevertheless the HIV-
C-speciﬁc binding antibody responses were detected in all other6, were immunised with 104 TCID50 and 105 TCID50 MV1-F4 respectively, on days 0
ow cytokine responses gated on CD8+ T cell. Dashed line represents the mean plus
macaques at day 14, except H31 in group B which seroconverted
after the second immunisation.
All vaccinees developed MV  neutralising antibodies after the
ﬁrst immunisation, boosted by the second (Fig. 5C and D).  Five
and seven vaccinees from group A and B, respectively, had measles
neutralising titres >1000 mIU/ml on day of boosting. Group B peak
MV neutralising antibody responses after the second immunisation
were signiﬁcantly greater (p = 0.0147, paired t-test), compared with
Group A.
3.3. CMI responses of MHC matched vaccinated macaques are not
identical
The MHC  haplotype and mean T cell cytokine response of vac-
cinated macaques is shown in Table 1. Signiﬁcant MHC class II
restricted CD4+ T cell responses were detected in 2 out of 4 het-
erozygous M1/M3  (H21, H22, H29 and H30), 3 out of 6 heterozygous
M2/M3  (H23, H28, H31, H34, H35 and H36) and 1 out of 2 heterozy-
gous M3/M4  (H25 and H33) macaques. In contrast, both MHC  class
II heterozygous M1/M2  (H24 and H32) and both heterozygous M6
recombinants (H25 and H27) gave signiﬁcant CD4+ T cell cytokine
responses. Signiﬁcant MHC  class I restricted CD8+ T cell responses
were detected in 1 out of 4 heterozygous M1/M3 (H21, H22, H29
and H30), and 1 out of 2 M1/M2  + M3  recombinants (H24 and H32)
macaques. In contrast, both heterozygous M2/M3  (H23 and H31)
macaques gave signiﬁcant CD8+ T cell cytokine responses.
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Fig. 3. Repertoire of cytokine responses to HIV-1 subtype C peptides following vaccination with MV1-F4. Single, double and triple cytokine (TNF+, IL-2+ and IFN+ cells)
responses by CD4+ (A and B) and CD8+ T cells (C and D) from peripheral blood, brachial lymph nodes (BLN) and spleen (SPL). Group A, macaques H21–H28 and group


























tingle  cytokine positive cells represented by IFN+ (blue), IL-2+ (green), TNF+ (re
L-2+TNF+  (orange), and triple cytokine positive cells represented by IL-2+IFN+T
. Discussion
In this study, we evaluated the immunogenicity of two  doses,
04 and 105 TCID50, of a measles vaccine vector, MV1-F4, carrying
n insert encoding HIV-1C Gag, RT and Nef, in non-human pri-
ates. Both doses of MV1-F4 stimulated T cell responses of similar
agnitude and breadth, in terms of the range of CMI  and humoral
esponses elicited. However, the beneﬁt of vaccination with the
igher dose was in higher titres of anti-F4 and MV neutralising
ntibodies, rather than improved T cell immunogenicity. These
ata might imply that there was a better Th2 response, missed
y the Th1 cytokine panel employed. Alternatively, neutralising
ntibodies may  have blunted vector infectivity, thereby limiting
urther increases in the frequency of CMI  responses. Superior
mmunogenicity was obtained after a second i.m. immunisation
emonstrating that MV1-F4 responses are boostable, in spite of
he presence of titres of vector neutralising antibodies known to
revent infection [27]. It is possible that the route of immunisation
ay  have helped overcome early vector neutralisation, compared
ith natural infection. Boosting earlier, prior to development of
igh titres of vector neutralising antibody, was not possible for efﬁ-
ient re-stimulation of memory responses as the primary immune
esponse did not wane sufﬁciently until day 84. Nevertheless, a
onger boost interval may  have improved CD8+ T cell cytokine
esponses, which had not markedly declined by day 84.
Cell mediated responses to MV  are dominated by CD4+ T cells
hat primarily produce a Th1-like pattern of cytokine releaseal cytokine positive cells represented by IFN+TNF+ (purple), IL-2+IFN+ (cyan),
(yellow) are plotted separately.
[28]. Therefore, it was  not unexpected for CD4+ T cell cytokine
responses to F4 peptides to be greater than CD8+ T cell responses.
Interestingly, responding CD4+ T cells were all CD154+, a marker
known to potently help dendritic cell maturation in priming
anti-viral CD8+ T cells [29]. Sporadic CD4+ and CD8+ T cell cytokine
responses detected in spleen taken at termination suggest that
MV1-F4 may  stimulate long lasting immunity. This would be
consistent with previous reports that MV-speciﬁc CD4+ and CD8+
T cells and MV-speciﬁc IgG can be detected up to 25 years after
vaccination [21,30]. Co-expression of the cytokines TNF, IFN and
IL-2 was determined in order to determine the fractions of single,
double and triple producers. As cytokine co-production capacity of
anti-viral CD4+ T cells is functionally superior to single-cytokine
producing cells it has been suggested that vaccines should aim
to elicit the former type of response [31]. The cytokine proﬁles
of CD4+ and CD8+ T cells observed indicate stimulation of a Th1
response characterized by the production of IFN-, IL-2 and TNF-
[32]. However, Th2 cytokines such as IL-4, IL-5 and IL-13 were
not assessed, so a Th1/Th2 mixed pattern of cytokine release
cannot be excluded. The bias of CD4+ T cell cytokine responses to
TNF and IL-2 suggests a central memory response rather than
terminally differentiated CD4 effector cell response characterised
by IFN- and TNF- [33]. By contrast, CD8+ memory T cells can
quickly produce a variety of cytokines including IFN, TNF and
to a lesser extent IL-2 [34], matching the proﬁle we observed
against HIV-1C peptides. The low frequency of multifunctional T
cells, positive for all three cytokines, is likely due to the necessary
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Fig. 4. T cell cytokine responses to MV  vector following vaccination with MV1-F4. Total cytokine (sum of TNF+, IL-2+ and IFN+ cells) response to MV  by CD4+ and CD8+ T
cells  from peripheral blood, brachial lymph nodes (BLN) and spleen (SPL). Group A, macaques H21–H28 and group B, macaques H29–H36, were immunised with 104 TCID50
a 5 axis, a


























[nd 10 TCID50 MV1-F4 respectively, on days 0 and 84. Time in days is shown on x-
esponses gated on CD4+ T cells. Panels C and D show cytokine responses gated on C
bove  which points were deemed signiﬁcant.
se of peripheral blood lymphocytes deﬁcient in effector memory
 cells when compared with mucosal sites [35,36]. Interest-
ngly, the cytokine proﬁle of lymphocytes from the spleen and
ymph nodes, lymphoid tissues rich in memory T cells, mirrored
hat of peripheral lymphocytes, when stimulated with HIV-1C
eptides.
The MHC  haplotype of a macaque confers a selective advan-
age for control of simian immunodeﬁciency virus (SIV) infection
37–40], via MHC-restricted anti-viral CMI  responses [41–44]. If
he distribution of MHC  haplotypes associated with either strong
r weak CMI  responses is uneven in comparative vaccine groups
hen bias may  occur, when measuring CMI  responses. For exam-
le, the M6  haplotype associated with strong control of simian
mmunodeﬁciency virus infection [37] here was also associated
ith strong CD4+ T cell responses against HIV-1C peptides follow-
ng vaccination, with the caveat that this observation applied to 2
acaques. Nevertheless, similar associations between HLA geno-
ype and measles vaccine humoral and cellular immune responses
ave been reported in man  [45]. Conversely, weak CMI  responses
ay  be associated with certain haplotypes, for example chronic
IV viremia is reportedly 80 times higher in MHC homozygous
ompared with heterozygous macaques [46,47]. Here, the alloca-
ion of heterozygous MHC-matched pairs of macaques resulted in a
emarkable consistency of responses across vaccines groups, com-
ared to a previous study where MHC  analysis was retrospective
19]. However, MHC  matched macaques did not give identical CMIll responses from PBMC unless preﬁxed by a tissue. Panels A and B shows cytokine
cell. Dashed line represents the mean plus 3 standard deviations of day 0 responses,
responses. Typically only half of MHC-matched macaques give sim-
ilar CMI  responses following vaccination. This result suggests other
factors such as prior Th1/Th2 bias, innate immunity status or minor
histocompatibility antigen may  have contributed to the restric-
tion of MHC-matched individual vaccine responses. For example
H24 did not seroconvert against HIV-1C but had strong CD4+ and
CD8+ CMI  responses against HIV-1C peptides, suggestive of Th1
bias, whereas MHC  matched H32 had weaker CMI responses but
seroconverted to F4, consistent with a balanced Th1/Th2 response.
Nevertheless, MHC  matching across groups has the potential to
reduce group variation, improve data interpretation and reduce
group sizes.
The presence of anti-MV immunity in nearly the entire adult
human population might restrict the use of recombinant MV  to
naïve infants, an already worthy goal. However, numerous stud-
ies have shown that revaccinating immunized individuals results
in a boost of anti-MV antibodies, suggesting that the attenuated
live vaccine replicates despite pre-existing immunity [48–50]. Like-
wise, the presence of maternal anti-MV antibodies has been shown
to limit the induction of humoral but not CMI  responses in immu-
nised infants [51]. Moreover, we  previously demonstrated that a
recombinant MV-HIV vector induces antibodies to HIV in mice and
macaques in the presence of pre-existing immunity [12], which
opens the possibility of their use to immunise adolescents and
adults. Clearly, this point needs to be further evaluated in human
trials.
R. Stebbings et al. / Vaccine 31 (2013) 6079– 6086 6085
























pV1-F4 immunisation of groups A (A) and B (B). Results are given as mid-point 
easured by plaque reduction assay of groups A (C) and B (D). Potency is given in 
nti-measles serum (97/648).
. Conclusions
In this study, boosting with MV1-F4 was able to efﬁciently over-
ome anti-vector neutralising antibodies, which have the potential
o blunt vaccine responses [52,53], to efﬁciently re-stimulate cel-
ular and humoral immune responses, making it a promising
andidate for a prime-boost vaccine strategy to limit the spread
f HIV. It is important to demonstrate that the use of these measles
ectors in the clinic elicits similar patterns of anti-HIV responses
n volunteers. It is also important to establish that CD4+ as well
s CD8+ anti-HIV responses can be beneﬁcial in a HIV vaccine.
HC typed Mauritian-derived cynomolgus macaques may  provide
 valuable model to investigate this further.
cknowledgements
The authors are grateful to the other members of the RMV-HIV
onsortium: Dr. Odile Launay (the Centre Cochin-Pasteur d’Essais
accinaux), Dr. Geert Leroux-Roels (Ghent University) and Dr.
avid Lewis (St. George’s University of London). The authors are
rateful to Anne Anderson (NIBSC) for assistance with measles neu-
ralisation assays.
Funding: This work was supported by the European Union
hrough the Sixth European Research Framework Programme
project number 2005-019043 RMV-HIV). GlaxoSmithKline Biolog-
cals S.A. partly funded this study. Funding to attend meetings was
rovided by EUROPRISE Network of Excellence on HIV vaccines
[ at which 50% maximal binding is achieved. Measles neutralising antibody titres
l calculated by direct comparison with the titre of 3rd International Standard for
and Microbicides (EC FP6 grant 037611). RS, NA, NR and MP  were
funded in part by the NIHR Centre for Research in Health Protection
at the Health Protection Agency.
References
[1] Hemelaar J, Gouws E, Ghys PD, Osmanov S. WHO-UNAIDS network for HIV
isolation and characterisation. Global trends in molecular epidemiology of HIV-
1  during 2000–2007. AIDS 2011;25:679–89.
[2] Ramanathan VD, Kumar M,  Mahalingam J, Sathyamoorthy P, Narayanan PR,
Solomon S, et al. A phase 1 study to evaluate the safety and immunogenicity
of  a recombinant HIV type 1 subtype C-modiﬁed vaccinia Ankara virus vaccine
candidate in Indian volunteers. AIDS Res Hum Retroviruses 2009;25:1107–16.
[3] Mehendale S, Sahay S, Thakar M,  Sahasrabuddhe S, Kakade M,  Shete A, et al.
Safety & immunogenicity of tgAAC09, a recombinant adeno-associated virus
type 2 HIV-1 subtype C vaccine in India. Indian J Med  Res 2010;132:168–75.
[4] Wecker M,  Gilbert P, Russell N, Hural J, Allen M,  Pensiero M,  et al. Phase I
safety and immunogenicity evaluations of an alphavirus replicon HIV-1 sub-
type C gag vaccine in healthy HIV-1-uninfected adults. Clin Vaccine Immunol
2012;19:1651–60.
[5] Grifﬁn JP. MMR  vaccination: how reassuring is reassurance. Adverse Drug React
Toxicol Rev 2001;20:1–2.
[6] Hilleman MR.  Current overview of the pathogenesis and prophylaxis of measles
with focus on practical implications. Vaccine 2001;20:651–65.
[7] Radecke F, Spielhofer P, Schneider H, Kaelin K, Huber M,  Dötsch C, et al. Rescue
of  measles viruses from cloned DNA. EMBO J 1995;14:5773–84.
[8] Tangy F, Naim HY. Live attenuated measles vaccine as a potential multivalent
pediatric vaccination vector. Viral Immunol 2005;18:317–26.
[9] Singh M,  Cattaneo R, Billeter MA. A recombinant measles virus expressing hep-
atitis B virus surface antigen induces humoral immune responses in genetically
modiﬁed mice. J Virol 1999;73:4823–8.
10] Wang Z, Hangartner L, Cornu TI, Martin LR, Zuniga A, Billeter MA,  et al. Recom-
binant measles viruses expressing heterologous antigens of mumps and simian











































[086 R. Stebbings et al. / Va
11] Combredet C, Labrousse-Najburg V, Mollet L, Lorin C, Delebecque F, Hurtrel
B,  et al. A molecularly cloned Schwarz strain of measles virus vaccine
induces strong immune responses in macaques and transgenic mice. J Virol
2003;77:11546–54.
12] Lorin C, Mollet L, Delebecque F, Combredet C, Charneau P, Hurtrel B, et al. A
single injection of recombinant measles vaccines expressing HIV-1 clade B
envelope glycoproteins induces neutralizing antibodies and cellular immune
responses to HIV. J Virol 2004;78:146–57.
13] Lorin C, Delebecque F, Labrousse V, Da Silva L, Lemonnier F, Brahic M,  et al.
A  recombinant live attenuated measles vaccine vector primes effective HLA-
A0201-restricted cytotoxic T lymphocytes and broadly neutralizing antibodies
against HIV-1 conserved epitopes. Vaccine 2005;23:4463–72.
14] Brandler S, Lucas-Hourani M,  Moris A, Frenkiel MP,  Combredet C, Février
M,  et al. Pediatric measles vaccine expressing a dengue antigen induces
durable serotype-speciﬁc neutralizing antibodies to dengue virus. PLoS NTD
2007;1:e96.
15] Guerbois M,  Moris A, Combredet C, Najburg V, Rufﬁé C, Février M,  et al. Live
attenuated measles vaccine expressing HIV-1 Gag virus like particles covered
with gp160V1V2 is strongly immunogenic. Virology 2009;388:191–203.
16] Liniger M,  Zuniga A, Morin TN, Combardiere B, Marty R, Wiegand M,  et al.
Recombinant measles viruses expressing single or multiple antigens of
human immunodeﬁciency virus (HIV-1) induce cellular and humoral immune
responses. Vaccine 2009;27:3299–305.
17] Brandler S, Rufﬁe C, Najburg V, Frenkiel MP,  Bedouelle H, Desprès P,
et  al. Pediatric measles vaccine expressing a dengue tetravalent antigen
elicits neutralizing antibodies against all for viruses. Vaccine 2010;28:
6730–9.
18] Brandler S, Marianneau P, Loth P, Lacôte S, Combredet C, Frenkiel MP,  et al.
Measles vaccine expressing the secreted form of West-Nile virus envelope gly-
coprotein induces protective immunity in squirrel monkeys, a new model of
West-Nile virus infection. J Infect Dis 2012;206:212–9.
19] Stebbings R, Février M,  Li B, Lorin C, Koutsoukos M,  Mee  E, et al. Immuno-
genicity of recombinant measles HIV-1 clade B candidate vaccine. PLoS ONE
2012;7:e50397.
20] Van Braeckel E, Bourguignon P, Koutsoukos M,  Clement F, Janssens M,  Car-
letti I, et al. An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional
cross-reactive CD4+ T cell responses in seronegative volunteers. Clin Infect Dis
2011;52:522–31.
21] Ovsyannikova IG, Dhiman N, Jacobson RM,  Vierkant RA, Poland GA. Frequency
of measles virus-speciﬁc CD4+ and CD8+ T cells in subjects seronega-
tive or highly seropositive for measles vaccine. Clin Diagn Lab Immunol
2003;10:411–6.
22] Choi YK, Simon MA,  Kim DY, Yoon BI, Kwon SW,  Lee KW,  et al. Fatal
measles virus infection in Japanese macaques (Macaca fuscata). Vet Pathol
1999;36:594–600.
23] El Mubarak HS, Yüksel S, van Amerongen G, Mulder PG, Mukhtar MM,  Osterhaus
AD,  et al. Infection of cynomolgus macaques (Macaca fascicularis) and rhesus
macaques (Macaca mulatta) with different wild-type measles viruses. J Gen
Virol 2007;88:2028–34.
24] Wiseman RW,  Wojcechowskyj JA, Greene JM,  Blasky AJ, Gopon T, Soma T,
et  al. Simian immunodeﬁciency virus SIVmac239 infection of major histo-
compatibility complex-identical cynomolgus macaques from Mauritius. J Virol
2007;81:349–61.
25] Mee  ET, Badhan A, Karl JA, Wiseman RW,  Cutler K, Knapp LA, et al. MHC  haplo-
type frequencies in a UK breeding colony of Mauritian cynomolgus macaques
mirror those found in a distinct population from the same geographic origin. J
Med  Primatol 2009;38:1–14.
26] Stebbings R, Berry N, Waldmann H, Bird P, Hale G, Stott J, et al. CD8+ lym-
phocytes do not mediate protection against acute superinfection 20 days after
vaccination with a live attenuated simian immunodeﬁciency virus. J Virol
2005;79:12264–72.
27] Lee MS, Nokes DJ, Hsu HM,  Lu CF. Protective titres of measles neutralising
antibody. J Med  Virol 2000;62:511–7.
28] Howe RC, Dhiman N, Ovsyannikova IG, Poland GA. Induction of CD4 T cell pro-
liferation and in vitro Th1-like cytokine responses to measles virus. Clin Exp
Immunol 2005;140:333–42.
29] Huang XL, Fan Z, Borowski L, Rinaldo CR. Maturation of dendritic cells for
enhanced activation of anti-HIV-1 CD8(+) T cell immunity. J Leukoc Biol
2008;83:1530–40.
30] Naniche D, Garenne M,  Rae C, Manchester M,  Buchta R, Brodine SK, et al.
Decrease in measles virus-speciﬁc CD4 T cell memory in vaccinated subjects. J
Infect Dis 2004;190:1387–95.
[31 (2013) 6079– 6086
31] Kannanganat S, Ibegbu C, Chennareddi L, Robinson HL, Amara RR. Multiple-
cytokine-producing antiviral CD4 T cells are functionally superior to single-
cytokine-producing cells. J Virol 2007;81:8468–76.
32] Abbas AK, Murphy KM,  Sher A. Functional diversity of helper T lymphocytes.
Nature 1996;383:787–93.
33] Sallusto F, Lenig D, Förster R, Lipp M,  Lanzavecchia A. Two subsets of memory
T  lymphocytes with distinct homing potentials and effector functions. Nature
1999;401:708–12.
34] Cho BK, Wang C, Sugawa S, Eisen HN, Chen J. Functional differences between
memory and naive CD8 T cells. Proc Natl Acad Sci U S A 1999;96:2976–81.
35] Campbell JJ, Murphy KE, Kunkel EJ, Brightling CE, Soler D, Shen Z, et al.
CCR7 expression and memory T cell diversity in humans. J Immunol
2001;166:877–84.
36] Picker LJ. Immunopathogenesis of acute AIDS virus infection. Curr Opin
Immunol 2006;18:399–405.
37] Mee  ET, Berry N, Ham C, Sauermann U, Maggiorella MT,  Martinon F, et al. Mhc
haplotype H6 is associated with sustained control of SIVmac251 infection in
Mauritian cynomolgus macaques. Immunogenetics 2009;61:327–39.
38] Mee  ET, Berry N, Ham C, Sauermann U, Maggiorella MT,  Martinon F, et al. Mhc
haplotype M3  is associated with early control of SHIVsbg infection in Mauritian
cynomolgus macaques. Tissue Antigens 2010;76:223–9.
39] Aarnink A, Dereuddre-Bosquet N, Vaslin B, Le Grand R, Winterton P, Apoil
PA, et al. Inﬂuence of the MHC  genotype on the progression of experimen-
tal  SIV infection in the Mauritian cynomolgus macaque. Immunogenetics
2011;63:267–74.
40] Cafaro A, Bellino S, Titti F, Maggiorella MT,  Sernicola L, Wiseman RW,  et al.
Impact of viral dose and major histocompatibility complex class IB haplo-
type on viral outcome in mauritian cynomolgus monkeys vaccinated with Tat
upon challenge with simian/human immunodeﬁciency virus SHIV89 6P. J Virol
2010;84:8953–8.
41] Ortiz AM,  Klatt NR, Li B, Yi Y, Tabb B, Hao  XP, et al. Depletion of CD4+ T cells
abrogates post-peak decline of viremia in SIV-infected rhesus macaques. J Clin
Invest 2011;121:4433–45.
42] Porichis F, Kaufmann DE. HIV-speciﬁc CD4 T cells and immune control of viral
replication. Curr Opin HIV AIDS 2011;6:174–80.
43] Schmitz JE, Kuroda MJ,  Santra S, Sasseville VG, Simon MA, Lifton MA,  et al.
Control of viremia in simian immunodeﬁciency virus infection by CD8+ lym-
phocytes. Science 1999;283:857–60.
44] Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, Blanchard J, et al. Dramatic rise
in  plasma viremia after CD8(+) T cell depletion in simian immunodeﬁciency
virus-infected macaques. J Exp Med  1999;189:991–8.
45] Ovsyannikova IG, Pankratz VS, Vierkant RA, Jacobson RM,  Poland GA. Consis-
tency of HLA associations between two independent measles vaccine cohorts:
a  replication study. Vaccine 2012;30:2146–52.
46] Penn DJ, Damjanovich K, Potts WK.  MHC  heterozygosity confers a selec-
tive  advantage against multiple-strain infections. Proc Natl Acad Sci U S A
2002;99:11260–4.
47] O’Connor SL, Lhost JJ, Becker EA, Detmer AM,  Johnson RC, Macnair CE, et al. MHC
heterozygote advantage in simian immunodeﬁciency virus-infected Mauritian
cynomolgus macaques. Sci Transl Med  2010;2:22ra18.
48] Sepúlveda-Amor J, Valdespino-Gómez JL, García-García Mde  L, Bennett J, Islas-
Romero R, Echaniz-Aviles G, et al. A randomized trial demonstrating successful
boosting responses following simultaneous aerosols of measles and rubella
(MR) vaccines in school age children. Vaccine 2002;20:2790–850.
49] Rager-Zisman B, Bazarsky E, Skibin A, Chamney S, Belmaker I, Shai I,
et  al. The effect of measles-mumps-rubella (MMR)  immunization on the
immune responses of previously immunized primary school children. Vaccine
2003;21:2580–8.
50] Wong-Chew RM,  Beeler JA, Audet S, Santos JI. Cellular and humoral immune
responses to measles in immune adults re-immunized with measles vaccine. J
Med  Virol 2003;2:276–80.
51] Gans H, DeHovitz R, Forghani B, Beeler J, Maldonado Y, Arvin AM.  Measles
and mumps vaccination as a model to investigate the developing immune
system: passive and active immunity during the ﬁrst year of life. Vaccine
2003;21:3398–405.
52] Lin J, Calcedo R, Vandenberghe LH, Figueredo JM,  Wilson JM.  Impact of preexis-
ting vector immunity on the efﬁcacy of adeno-associated virus-based HIV-1
Gag  vaccines. Hum Gene Ther 2008;19:663–9.
53] Pichla-Gollon SL, Lin SW,  Hensley SE, Lasaro MO,  Herkenhoff-Haut L, Drinker M,
et  al. Effect of preexisting immunity on an adenovirus vaccine vector: in vitro
neutralization assays fail to predict inhibition by antiviral antibody in vivo. J
Virol 2009;83:5567–73.
